Abstract
A series of substituted 2,3-dihydrophthalazine-l,4-dione derivatives as well as the corresponding N,N-diaminophthalamides were prepared and were demonstrated to have potent hypolipidemic activity, lowering both serum triglyceride and cholesterol levels significantly at 20 mg/kg/day after 16 days of dosing in CF1 male mice. The parent compound, 2,3-dihydrophthalazine-l,4-dione, lowered serum cholesterol 51% and serum triglyceride 43%. 2-(2-Carboxyethyl)-2,3-dihydrophthalazine-l,4-dione demonstrated the best hypocholesterolemic activity, with a 66% reduction after 16 days. The 2-(p-chlorophenyl) derivative demonstrated good activity (>40% reduction) in both screens, as did the 6-methyl-2,3-dihydrophthalazine-l,4-dione derivative. Of the amides, 4-methyk N,N-diaminophthalamide demonstrated the best hypolipidemic activity, affording a greater than 40% reduction. 2,3-Dihydrophthalazine-l,4-dione was found to inhibit the enzyme activity of acetyl CoA synthetase, ATP-dependent citrate lyase, sn-glycerol-3-phosphate acyl transferase, phosphatidylate phosphohydrolase, and mitochondrial citrate exchange of liver. In mice after 16 days of dosing, there was a reduction of cholesterol, triglycerides, neutral lipids, and phospholipids in the liver. Cholesterol and neutral lipids were reduced in rat chylomicrons, very low-density lipoproteins, and low-density lipoproteins. The cholesterol content of the high-density lipoprotein fraction was slightly elevated, but reductions in the triglycerides and phospholipids were observed in this lipoprotein fraction. 3H-Cholesterol distribution studies showed a lower concentration in the major organs and plasma, with a higher 3H-cholesterol content in the stomach and large intestine.
Similar content being viewed by others
REFERENCES
J. M. Chapman, Jr., S. D. Wyrick, P. H. Voorstad, J. H. Maguire, G. H. Cocolas, and I. H. Hall. J. Pharm. Sci. 73:1482–1484 (1984).
I. H. Hall, P. J. Voorstad, J. M. Chapman, Jr., and G. H. Cocolas. J. Pharm. Sci. 72:1192–1198 (1983).
I. H. Hall, J. M. Chapman, Jr., P. J. Voorstad, and G. H. Cocolas. J. Pharm. Sci. 73:956–961 (1984).
S. D. Wyrick, P. J. Voorstad, G. H. Cocolas, and I. H. Hall. J. Med. Chem. 27:768–772 (1984).
P. J. Voorstad, I. H. Hall, and G. H. Cocolas. Pharm. Res. 6:250–255 (1984).
N. P. Buu-Hoi, H. L. Bihan, and F. Binon. Rec. Trav. Chim. 70:1099–1104 (1951).
D. Biguard and P. Grammaticakis. Bull. Soc. Chim. 9:675–689 (1942).
A. L. Berre, M. Dormoy, and J. Godin. C.R. Acad. Sci. 261:1872–1875 (1965).
H. Feuer, G. B. Silverman, H. P. Angstadt, and A. R. Faulke. J. Org. Chem. 27:2081–2084 (1962).
J. J. Blanksma and H. A. Bakels. Rec. Trav. Chim. 58:497–513 (1939).
E. H. White, D. F. Roswell, and O. C. Zatinou. J. Org. Chem. 34:2462–2468 (1968).
J. Nishie. Nippon Kagaku Zaashi 87:1239–1262 (1966).
F. D. Chattaway and T. William. J. Chem. Soc. 117:711–720 (1920).
A. T. Ness, J. V. Pastewka, and A. C. Peacock. Clin. Chim. Acta. 10:229 (1964).
I. H. Hall, P. J. Voorstad, J. M. Chapman, Jr., and G. H. Cocolas. J. Pharm. Sci. 72:845 (1983).
J. T. Litchfield, Jr., and F. Wilcoxon. J. Pharmacol. Exp. Ther. 96:99 (1949).
A. G. Goodridge. J. Biol. Chem. 248:4318 (1973).
M. Hoffman, L. Weiss, and O. H. Wieland. Anal. Biochem. 84:441 (1978).
B. H. Robinson and G. R. Williams. Biochim. Biophys. Acta 216:63 (1970).
B. H. Robinson, G. R. Williams, M. L. Halperin, and C. C. Leznoff. 15:263 (1970).
S. Shefer, S. Hauser, and E. H. Mosbach. J. Lipid Res. 9:328 (1978).
G. T. Haven, J. R. Krzemien, and T. T. Nguyen. Res. Commun. Chem. Pathol. Pharmacol. 6:253 (1973).
F. Wada, K. Hirata, and Y. Sakamito. J. Biochem. 65:171 (1969).
M. D. Greenspan and J. M. Lowenstein. J. Biol. Chem. 243:6273 (1968).
R. O. Brady, R. M. Bradley, and E. G. Trams. J. Biol. Chem. 235:3093 (1960).
R. G. Lamb, S. D. Wyrick, and C. Piantadosi. Atherosclerosis 27:147 (1977).
R. D. Mavis, N. Jacob, J. N. Finkelstein, and B. P. Hall. J. Lipid Res. 19:467 (1978).
S. Balasubramaniam, K. A. Mitropoulos, and S. Venkatesan. Eur. J. Biochem. 90:377 (1978).
A. Chait, P. H. Iverius, and J. D. Brunzell. J. Clin. Invest. 69:490 (1982).
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. J. Biol. Chem. 193:265 (1951).
E. G. Bligh and W. J. Dyer. Can. J. Biochem. Physiol. 37:911 (1959).
J. Folch, M. Lees, and G. H. C. Stanley. J. Biol. Chem. 226:497 (1957).
J. H. Bragdon. J. Biol. Chem. 190:513 (1951).
C. P. Stewart and E. G. Hendry. Biochem. J. 29:1683 (1935).
F. T. Hatch and R. S. Lees. Adv. Lipid Res. 6:1 (1968).
R. J. Havel, H. A. Eder, and J. H. Bragdon. J. Clin. Invest. 34:1345 (1955).
T. A. Miettinen, J. K. Huttunen, T. Strandberg, V. Naukkarinen, S. Mattila, and T. Kumlin. Lancet 2:478 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murthy, A.R.K., Hall, I.H., Chapman, J.M. et al. The Hypolipidemic Activity of a Series of 2,3-Dihydrophthalazine-l,4-dione Derivatives in Rodents. Pharm Res 3, 93–101 (1986). https://doi.org/10.1023/A:1016341403244
Issue Date:
DOI: https://doi.org/10.1023/A:1016341403244